AOD-9604

AOD-9604 is a synthetic 16-amino-acid fragment corresponding to the C-terminal region (residues 176-191) of human growth hormone, modified with an additional stabilizing amino acid. The design rationale, developed at Monash University in the 1990s, was to isolate the region of the GH molecule proposed to drive lipolysis (fat breakdown) and inhibition of lipogenesis (fat storage) while removing the region responsible for GH's growth-promoting and insulin-desensitizing effects, since the fragment does not bind the classical GH receptor in the same way as full-length GH. In early rodent studies it was reported to stimulate hormone-sensitive lipase and inhibit acetyl-CoA carboxylase in adipose tissue, reducing body-weight gain and adipocyte size in obese Zucker rats without inducing insulin resistance or elevating IGF-1.

Evidence for AOD-9604 is dominated by preclinical (in vitro and rodent) work from the original Monash/Metabolic Pharmaceuticals research program, which reported lipolytic activity and reduced weight gain in obese rodent models without the adverse metabolic effects of intact GH. This preclinical promise did not translate to humans: the developer's own pivotal Phase IIb trial (a multi-week, placebo-controlled study in several hundred adults with obesity) failed to show a statistically significant reduction in body weight versus placebo, and the obesity drug-development program was discontinued around 2007-2008. AOD-9604 has never completed a successful Phase 3 program and is not an approved medicine for weight loss or any other indication in the US, EU, or elsewhere; it remains sold only as a research chemical, with human efficacy data limited to a discontinued, unsuccessful program.

Educational overview only — no dosing instructions in the public hub.

In the clinical trials that were run, AOD-9604 was generally reported as well tolerated with a safety profile similar to placebo, and — unlike full-length GH — did not appear to raise IGF-1 or impair insulin sensitivity at studied doses. However, that safety database is limited, dated, and was collected under a discontinued development program; it does not extend to the unregulated "research peptide" products sold today, which carry the usual risks of unverified sourcing: injection-site reactions, unknown impurities, incorrect concentration, and no oversight of manufacturing quality. Because the pivotal efficacy trial failed, any product marketed for fat loss is doing so without clinical support.

Because AOD-9604 is not an approved pharmaceutical, every unit in circulation is a research chemical of variable provenance. Third-party certificates of analysis (CoA) from an independent laboratory — covering HPLC purity, mass spectrometry identity confirmation, and quantification of peptide content (not just gross weight) — are the only meaningful way to assess whether a given vial matches its label, since there is no regulatory batch oversight equivalent to a licensed drug product.

Not an approved drug in any major market (FDA, EMA, or otherwise); its Phase IIb obesity program was discontinued after failing to beat placebo. It is generally sold and marketed as a "research chemical" or "not for human consumption," a framing that reflects its unapproved status rather than confirmed safety or efficacy for personal use.